Contact the committee
Contact the committee c/o Stella Galea, Faculty & Committee Manager
Professor Baldwin aims to improve clinical outcomes in mood and anxiety disorders: by investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes; and by offering a tertiary referral specialist clinical service to patients with chronic and treatment-resistant conditions.
Declaration of interestsPersonal pecuniary interests: In the last three years (September 2014–August 2017), I have received honoraria for giving educational lectures in meetings organised by AstraZeneca, Janssen, H. Lundbeck A/S, Pierre Fabre and Pfizer. I have received financial support from the Ministry of Defence relating to my membership of its Research Ethics Committee. I have also received financial support from the Wiley publishing company relating to my editorship of the Human Psychopharmacology journal.
Personal family interest: My wife has received a personal honorarium for participating in an advisory board organised by H. Lundbeck A/S.
Non-personal pecuniary interest: In the last three years, my employer has received reimbursement for my time spent in attendance at advisory board meetings organised by Liva Nova and Mundipharma.
Personal non-percuniary interest: I am a Medical Patron of Anxiety UK and the University-nominated Governor on the Board of Southern Health NHS Foundation Trust (April 2017 onwards).
Professor Allan Young holds the Chair of Mood Disorders at King’s College London where he is also Director of the Centre for Affective Disorders within the Department of Psychological Medicine in the Institute of Psychiatry. He has held academic appointments at the Universities of Oxford, Newcastle upon Tyne (latterly holding the Chair of General Psychiatry at Newcastle), UBC, Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London where he held the Chair of Psychiatry and was Director of the Centre for Mental Health.
Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, and the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA) and numerous other funding agencies. He has published over 300 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including ‘Bipolar disorders: basic mechanisms and therapeutic implications’ (2nd Ed.) with JC Soares, and ‘Practical management of bipolar disorder’ with IN Ferrier and E Michalak (Cambridge University Press, 2010).
Professor Young is a member of a number of editorial boards and is a member of numerous professional and scientific societies. He is currently Treasurer of the International Society for Affective Disorders and Chair of the Psychopharmacology group of the Royal College of Psychiatrists. Professor Young also acts as an expert witness.
Declaration of interests
Employed by King’s College London; Honorary Consultant SLaM (NHS UK).
Paid lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders.
No share holdings in pharmaceutical companies.
Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study.
Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth.
Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK).
I am Professor of Clinical Psychiatry at Imperial College, London, Honorary Consultant Psychiatrist at the West London Mental Health NHS Trust, and joint-head of the Prescribing Observatory for Mental Health (POMH-UK).
In 1987, I set up one of the first tertiary-referral services for treatment-resistant schizophrenia. The main focus of my clinical research over the last 30 years has been schizophrenia, with a particular interest in the rational treatment of the condition. I have led investigations that have covered psychological and pharmacological treatment interventions for the condition and investigated antipsychotic drug side effects (particularly extrapyramidal movement disorders; the reliability, validity and clinical utility of the Barnes Akathisia Rating Scale have been independently demonstrated, and it is the scale most frequently used to assess this condition, world-wide), as well as phenomenology, neurocognition and comorbid substance use, including a Wellcome-funded, first-episode psychosis study. My work has generated over 250 publications.
Recent research experience includes PI for the CUtLASS trial, and chair of the IDMECs for the BALANCE and CEQUEL trials. I am currently CI for the HTA-funded ACTIONS and AMICUS trials, PI for the BeneMin study, and chair of the Trial Steering Committees for the NESS and CIRCLE studies. I am a past member of the Committee on Safety of Medicines, past Chair of the Royal College of Psychiatrists’ Special Interest Group in Psychopharmacology, and past President of the British Association for Psychopharmacology. I was a member of the NICE schizophrenia guideline development group (and chair of the pharmacology subcommittee) in 2002 and for the guideline update in 2009.
Sam Chamberlain is a Wellcome Trust Fellow and Honorary Consultant Psychiatrist, at the University of Cambridge Department of Psychiatry, and Cambridge & Peterborough NHS Foundation Trust. His work focuses on the neurobiology and treatment of impulsive, compulsive, and behaviourally-addictive disorders. Key examples include attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorders, and gambling disorder. These conditions are common, functionally impairing, but often hidden and under-treated.
Dr Chamberlain’s research uses clinical measures, cognitive tests, and biomarkers (such as brain imaging and genetics) to better understand why impulsive and compulsive problems develop; and how they can be better treated. He has contributed to the development of new clinical rating scales / instruments; and to a number of treatment studies. For example, along with collaborators in the USA, he found that n-acetyl cysteine (an antioxidant and amino-acid precursor) improved symptoms of skin picking disorder; and enhanced long-term outcomes when used alongside psychotherapy in gambling disorder.
Dr Chamberlain has published widely, including first-authored papers in Science, the American Journal of Psychiatry, Biological Psychiatry, and the Archives of General Psychiatry. He is co-author of several books including ‘Clinical Guide to Obsessive Compulsive and Related Disorders' and ‘Why Can't I Stop? Reclaiming Your Life from a Behavioral Addiction’. He is Associate Editor at Neuroscience and Biobehavioral Reviews, and acts as reviewer for a variety of journals and organizations. Dr Chamberlain has received the Wyeth Award for Psychopharmacology from the British Association for Psychopharmacology, and a Clinical Fellowship from the Wellcome Trust.Declaration of Interest form
In my work I employ a translational approach to study how genetic and environmental factors enhance risk for mental illness.
I am particularly interested in how identified genetic risk factors affect learning processes in the brain; abnormalities in which underlie the key symptoms seen in a range of mental health problems.
Overall I believe that understanding how genetic risk factors influence the brain and how these responses are modulated by environmental stimuli is crucial to the development of new treatments for psychiatric illness.
In addition to my pre-clinical work I also conduct clinical work and research in the fields of adult neurodevelopmental disorders and early psychosis.
Declaration of interests
His research interests centre on the causes and treatment of psychosis. His recent work has focussed on understanding the role of dopamine and neuroinflammation in the development of psychosis, the effects of antipsychotic drugs on the nervous and endocrine systems, & the causes of cognitive impairment in schizophrenia. This work has been recognised through a number of awards including the Schizophrenia International Research Society Rising Star Award 2013, European Psychiatric Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), Royal College of Psychiatrists research prize (2005), and the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007). He was made an honorary associate of the European College of Neuropsychopharmacology in 2006.
Other career highlights include working as a junior potato scrubber on a farm. He spends his spare time selflessly trying to find the world’s best ice cream.
Declaration of interests
Employed by King’s College London and Honorary Consultant at SLaM (NHS UK).
No share holdings in pharmaceutical or medical device companies.
Has received funding from Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche for investigator initiated studies and/or for participation in advisory boards, speaker bureau and/or educational events.
Main grant funding (past and present): MRC (UK), Wellcome Trust, and European Union.
Professor McAllister-Williams has been employed by Newcastle University since 1995, initially as a Clinical lecturer, then as an MRC Clinician Scientist Fellow and subsequently a Reader in Clinical Psychopharmacology. In 2017 he was promoted to a Personal Chair. Clinically, he is the lead consultant in the tertiary level Regional Affective Disorders Service based in Newcastle. This is the oldest and one of the largest such service in the UK providing outpatient and inpatient services for patients with treatment refractory mood disorders. Referrals to the service are received from across the UK and internationally. Professor McAllister-Williams research focuses on the pathophysiology and treatment of both bipolar and unipolar affective disorders. He is a past General Secretary of the British Association for Psychopharmacology (BAP) and was appointed in 2012 as the BAP Director of Education. He is a major contributor to their CPD programme.
Declaration of interests
Professor McAllister-Williams has received speaker and consultancy fees, support for attending meetings and independent investigator led research awards from a number of pharmaceutical companies over several years including AstraZeneca, Bristol Myers-Squibb, Cyberonics, Eli Lilly, Ferrer, GlaxoSmithKline, Janssen-Cilag, LivaNova, Lundbeck, Merck Sharp & Dohme, My Tomorrows, Otsuka, Pfizer, Roche, Servier, SPIMACO, Sunovion and Wyeth. The vast majority of such monies have been paid to his employer, Newcastle University. Neither he nor any of his immediate family hold any shares in, or have on-going financial relationships with, any pharmaceutical company.
Adrian is Consultant Forensic Psychiatrist at Langdon Hospital in Dawlish, Devon. He is a former Medical Director of Devon Partnership NHS Trust and Founding Chair of the School of Psychiatry at the Peninsular Deanery (2006-2008).
He was the elected Chair of the South West Division of the Royal College of Psychiatrists (2007-2011) and sat on the College Council in this capacity. In 2010 he was appointed Chair of the Westminster Parliamentary Liaison Committee of the Royal College of Psychiatrists (attending the three main Party Conferences 2011-14 in this capacity).
He was Clinical Director for Mental Health, Dementia and Neurology, working for NHS England South West (2013-2015, interim from 2012-13). He has also acted as a Reviewer and Clinical Expert for the Healthcare Commission and its successor organisation the Care Quality Commission (CQC).
I have a keen interest in Compliance, Concordance and Adherence when it comes to prescribing. I have publications in OCD, Depot antipsychotics and Physiccal Health monitoring. The relationship between Depression, Anxiety and Pain attracts my attention both clinically and from the research point of view. I am continuously developing my knowlegde and skills in the interface between medical ethics and the law.
Declaration of interests
I have no direct business or shares with any pharmaceutical company.
I receive no grants for research.
I get paid agreed honoraria for delivering educational and not promotional talks both nationally and internationally.
Dr Stokes has received research funding support from Corcept Therapeutics Inc. He has received grant funding from the Medical Research Council UK for a collaborative study with Janssen Research and Development LLC. Janssen Research and Development LLC are providing non-financial contributions to support this study. Dr Stokes has received expenses to attend conferences, and fees for lecturing and consultancy work (including attending an advisory board) from Corcept Therapeutics, Indivior, and Liva Nova.